Bhandari M., Schemitsch E.H., Karachalios T., Sancheti P., Poolman R.W., Caminis J., Daizadeh N., Dent-Acosta R.E., Egbuna O., Chines A., Miclau T. (2020)
BACKGROUND: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate ...